Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NEOMED Therapeutics
Montreal, Quebec, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
NEOMED Therapeutics (now operating as EPIGeNE Therapeutics) is a clinical-stage biotechnology company based in Montreal, Canada, that was spun out from the NEOMED Institute (now adMare BioInnovations). The company focuses on developing novel, orally bioavailable epigenetic inhibitors for the treatment of various cancers. Its lead candidate, NEO2734 (also known as EP31670), is a first-in-class dual inhibitor of BET and CBP/P300 proteins, currently being evaluated in Phase 1 clinical trials for advanced solid tumors and hematological malignancies. The company's pipeline also includes programs targeting SMARCA4 and follow-on dual inhibitors, aiming to overcome resistance to traditional epigenetic therapies.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
EpigenetixadMare BioInnovationsUniversity of Miami
Beyond the preview
Go deeper on NEOMED Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEOMED Therapeutics.